Peptides in 2TM · Zenagamtide / Amycretin

Behind the film: Zenagamtide / Amycretin references & context

Peptides in 2 — Episode 12: One peptide, complementary signals. Evidence cutoff: October 13, 2026. Published October 14, 2026. Educational information, not medical advice. WPF does not sell peptides. Source checking is distinct from independent scientific review; no independent human scientific review or institutional endorsement is claimed.

Identity and mechanism

Zenagamtide was previously called amycretin. It is one engineered peptide, distinct from the two separate ingredients in CagriSema. The 2026 clinical publications describe activity at GLP-1, amylin and calcitonin receptors. For accuracy, the film therefore uses “complementary signals” rather than implying exactly two receptor targets. The revised structural scene shows experimentally derived receptor architecture. It does not show zenagamtide binding, a peptide bridging three receptors, or equal potency at every receptor.

Primary records: oral phase 2 paper and injectable phase 2 paper. The supporting institutional records reproduce their abstracts: oral and injectable.

Development history and credit

Novo Nordisk is the developer. Agnes Gasiorek and colleagues reported the first-in-human oral study in 2025. The paper lists research affiliations in Måløv and other Danish locations; the trial was conducted at a research unit in San Antonio, Texas. The two regional maps identify Måløv and San Antonio as affiliation and study-city context. These markers do not locate an exact discovery room, manufacturing plant, or every participating institution. Publication dates are not invention dates. Neither the first author nor the clinical investigator is described as the sole inventor.

Gasiorek A et al. The Lancet 406:135–148 (2025). DOI 10.1016/S0140-6736(25)01176-601176-6); PubMed 40550229.

Related injectable early study: Dahl K et al. The Lancet 406:149–162 (2025). DOI 10.1016/S0140-6736(25)01185-701185-7); PubMed 40550231. The film does not use its early obesity weight-loss figures as a comparison with the later diabetes studies.

Published 2026 oral evidence

Mora and colleagues reported 186 randomized participants in the oral analysis. Adults had type 2 diabetes and received background metformin, with or without an SGLT2 inhibitor. At 36 weeks, estimated HbA1c declines ranged from 0.9 to 1.4 percentage points across active dose groups. The primary efficacy estimand used on-treatment observations without rescue medication. Gastrointestinal events were common; serious adverse events occurred in active groups. The film does not equate these findings with proof of long-term safety.

Mora P et al. The Lancet 408:607–620 (2026). DOI 10.1016/S0140-6736(26)01247-X01247-X); PubMed 42532079.

Published 2026 injectable evidence

The separate injectable analysis included 262 randomized participants, 261 exposed to treatment. At 36 weeks, estimated HbA1c declines ranged from 0.9 to 1.7 percentage points across active dose groups. Its primary analysis also used the efficacy estimand. Gastrointestinal and serious adverse events were reported. The study is associated with 83 sites across 11 countries; a map of Denmark and Texas must not be mistaken for its complete geography.

Mora P et al. The Lancet 408:621–635 (2026). DOI 10.1016/S0140-6736(26)01248-101248-1); PubMed 42532080. The research records identify NCT06542874.

Reading the exact graphic

The horizontal intervals show the smallest and largest estimated mean HbA1c reductions across the active dose groups in each published route analysis: injectable 0.9–1.7 and oral 0.9–1.4 percentage points. They are not confidence intervals, participant-level response ranges, estimates of weight loss, or a ranking of routes. Values are displayed as magnitudes of reductions; the underlying changes are negative. The endpoints and complete intervals remain visible throughout the scene.

The oral and injectable findings must not be treated as a head-to-head route trial. A percentage-point change in HbA1c differs from a relative percentage reduction. HbA1c provides information about longer-term glucose exposure; it does not by itself establish cardiovascular, kidney or mortality benefit. The short film presents selected evidence rather than all endpoints, dose groups, adverse events or confidence intervals. Refer to the complete publications for those details. Trial doses are not self-treatment instructions, and the film gives none.

Development status

At the cutoff, Novo describes zenagamtide as under development for obesity in AMAZE and type 2 diabetes in AMBITION, investigating both oral and subcutaneous administration. Development programmes, phase advancement and positive results are not regulatory approval or commercial availability. The film does not promise approval, worldwide access, purchasing options or formulation interchangeability. Future results and regulatory decisions can change this account.

Novo Nordisk September 16, 2026 announcement and current R&D pipeline. These are company sources, identified as such. All cited clinical work was sponsored by Novo Nordisk; consult each paper’s conflict disclosures.

Original artwork, motion and rights

Four new image-generation artworks were created specifically for this film: a precision synthesis-style instrument, a tablet dissolution research chamber, analytical capillary equipment, and a synchrotron-style beamline hall. They are conceptual educational scenes, not documentary photographs of actual Novo facilities, trial equipment, a marketed zenagamtide tablet, patient samples, or proof of any experimental result. They do not establish that these precise instruments were used in the cited studies. No earlier episode artwork is used as their source or edit target.

Each content image appears in one scene only. Revised code-rendered scenes show clear regional maps, a slow camera orbit around receptor backbones and an exact-value clinical graphic. The maps replace the earlier spinning globe. The earlier moving bead schematic has been removed.

The receptor scene uses PDB 6KJV, an engineered inactive human GLP-1 receptor transmembrane domain, and PDB 7TYX, an AMY2 receptor complex. In 6KJV, only the receptor backbone is displayed: T4 lysozyme fusion residues are omitted. In 7TYX, only calcitonin receptor and RAMP2 backbones are displayed; the bound rat amylin, G proteins and other components are omitted. Smooth tubes follow resolved alpha-carbon coordinates, with breaks at unresolved stretches. These are receptor-context structures, not zenagamtide complex structures, molecular dynamics or a demonstration of binding. Colours, display scale, orientation and camera motion are presentation choices. The engineered GLP-1R construct is not a full native receptor.

Coordinate publications: Xu et al., IUCrJ (2019), DOI 10.1107/S2052252519013496, PMID 31709055; Cao et al., Science (2022), DOI 10.1126/science.abm9609, PMID 35324283. The scene does not present either study as testing zenagamtide.

The geographic geometry is Natural Earth public-domain data. Regional map composition and markers are new for Episode 12. Geographic base data are reused as data, not previously rendered film artwork. The Montserrat font uses the included SIL Open Font License.

The established WPF brand image recurs. All spoken audio, including the closing, comes from one newly generated continuous Tom voice performance. The older closing recordings are excluded. The shorter script and slower generation setting replace the accelerated first version; no post-production voice speed-up is applied. No real researcher's voice is cloned. The new instrumental score from the first version is retained. No paid video generation was used. Picture motion, diagrams, overlays, audio editing and rendering were produced locally.

Technical delivery and captions

Target export: 1920×1080, 24 fps, exactly 120 seconds, stereo AAC. Scene boundaries follow measured narration. The full closing finishes before the final picture fade: “Peptides in 2. World Peptide Foundation. Every experience matters.” English SRT and VTT captions are separate and optional. Their timing uses recognition-assisted word timestamps, with scientific names, numerical notation and transcription errors corrected. These timestamps are not a claim of independent human caption review.

The revised source pack contains the retained artwork, receptor coordinates and provenance, geographic data, font licence, continuous narration, music, brand image, production scripts, word timestamps, measured timing, captions, transcript, plan, notes and validation. Earlier voice chunks and closing recordings are excluded. Temporary signed generation URLs and upload helpers are excluded. Source verification does not equal independent scientific endorsement. Corrections and useful primary sources: admin@worldpeptidefoundation.org. Scientific studies and self-reported experiences remain distinct forms of information.